Abstract
The size of anticancer agent-incorporating micelles can be controlled within the diameter range of 20-100 nm to ensure that they do not penetrate normal vessel walls. With this development, it is expected that the incidence of drug-induced side-effects may be decreased owing to the reduced drug distribution in normal tissue. Micelle systems can also evade non-specific capture by the reticuloendothelial system because the outer shell of a micelle is covered with polyethylene glycol. Consequently, a polymer micelle carrier can be delivered selectively to a tumor by utilizing the enhanced permeability and retention effect. Moreover, a water-insoluble drug can be incorporated into polymer micelles. Presently, several anticancer agent-incorporating micelle carrier systems are under preclinical and clinical evaluation. Furthermore, nucleic acid-incorporating micelle carrier systems are also being developed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / pharmacology
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / pharmacology
-
Clinical Trials as Topic
-
Doxorubicin / administration & dosage
-
Doxorubicin / pharmacology
-
Drug Carriers / chemistry
-
Drug Delivery Systems
-
Drug Evaluation, Preclinical
-
Humans
-
Micelles*
-
Nanoparticles / chemistry
-
Paclitaxel / administration & dosage
-
Paclitaxel / analogs & derivatives
-
Paclitaxel / pharmacology
-
Particle Size
-
Polyethylene Glycols / chemistry
-
Polymers / chemistry*
-
Zinostatin / administration & dosage
-
Zinostatin / pharmacology
Substances
-
Antibiotics, Antineoplastic
-
Antineoplastic Agents
-
Antineoplastic Agents, Phytogenic
-
Drug Carriers
-
Micelles
-
NK105
-
Polymers
-
Polyethylene Glycols
-
Doxorubicin
-
Zinostatin
-
Paclitaxel